OOIR: Observatory of International Research

Papers

(The H4-Index of Antiviral Research is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination	382
Editorial Board	117
Editorial Board	102
Editorial Board	86
Corrigendum to “Crystal structure and cap binding analysis of the methyltransferase of langat virus” [Antivir. Res. 208 (2022) 105459]	79
Editorial Board	68
Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical study	60
Long-term and efficient inhibition of hepatitis B virus replication by AAV8-delivered artificial microRNAs	58
Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models.	52
A novel model based on qAnti-HBc and conventional biomarkers for identifying significant liver injury among CHB patients with ALT ≤ ULN	47
Progress in novel delivery technologies to improve efficacy of therapeutic antibodies	42
A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy	41
Novel inhibitors of HSV-1 protease effective in vitro and in vivo	38
Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models	37
Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier	37
Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice	36
Targeted inhibition of IGF2BP1 effectively suppresses HBV replication via an m6A-dependent manner	35
Structural and quantitative comparison of viral infection-associated N-glycans in plasma from humans, pigs, and chickens: Greater similarity between humans and chickens than pigs	35
Corrigendum to “The novel therapeutic target and inhibitory effects of PF-429242 against Zika virus infection” [Antivir. Res. vol 192 (2021) 1–13/105121]	34
Editorial Board	33
Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections	33
Methyl rosmarinate is an allosteric inhibitor of SARS-CoV-2 3 CL protease as a potential candidate against SARS-cov-2 infection	33
The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection	32
Chemical-induced degradation of PreS2 mutant surface antigen via the induction of microautophagy	32
Long-term effects of peginterferon-based therapy versus nucleos(t)ide analogue monotherapy in non-cirrhotic HBeAg-positive chronic hepatitis B patients	32

Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals	32
Conserved use of the sodium/bile acid cotransporter (NTCP) as an entry receptor by hepatitis B virus and domestic cat hepadnavirus	32
JNJ-7184, a respiratory syncytial virus inhibitor targeting the connector domain of the viral polymerase	30